August 14, 2026

FDA approves iberdomide for multiple myeloma

MRD-negative complete response occurred in 41% of patients receiving ZDd vs 21% with DVd in the phase 3 EXCALIBER-RRMM trial.

MDSpire News

August 13, 2026

Medical Oddities: Not a feces sign, a wine cork

Imaging twists, intimacy rules, kombucha, and stress biology keep science delightfully odd.

MDSpire News

August 12, 2026

PET/CT May Improve Detection of Local CRC Liver Metastasis Progression

The combined imaging approach improved detection of local recurrence and extrahepatic disease during early posttreatment follow‐up for colorectal liver metastases.

MDSpire News

August 12, 2026

How Often Is Thyroid Hormone Needed After Hemithyroidectomy?

Nearly 40% of patients initiated thyroid hormone therapy within 2 years of hemithyroidectomy, with higher preoperative thyroid‐stimulating hormone levels and thyroid cancer identifying those at greatest risk.

MDSpire News

August 10, 2026

FDA Approves Melanoma BRAF Companion Test

The assay is indicated to identify patients with advanced melanoma who have BRAF V600E or BRAF V600K variants and may benefit from FDA-approved targeted therapies.

MDSpire News

August 10, 2026

New Screen May Expand Molecular Glue Discovery

A multiplexed screening platform identified a glutathionylation-activated DCAF11 molecular glue, revealing a previously unrecognized mechanism of targeted protein degradation.

MDSpire News

August 07, 2026

FDA Approves Viral Therapy Plus Nivolumab

Accelerated approval is based on objective response rate and duration of response in advanced melanoma, with postapproval trials required to confirm clinical benefit.

MDSpire News

August 05, 2026

AI-Assisted MRI Method May Rival CT in Lung Nodule Detection

A rapid AI‐assisted imaging protocol detected nearly all clinically relevant solid lung nodules while closely matching CT for suspicious screening classifications.

MDSpire News

August 03, 2026

FDA Approves Pluvicto for Hormone-Sensitive Prostate Cancer

The approval is based on phase 3 PSMAddition results showing reduced risk of disease progression or death with Pluvicto plus standard of care compared with standard of care alone, according to Novartis.

MDSpire News

July 31, 2026

Postsurgical Ensartinib in ALK-Positive NSCLC

Adjuvant ensartinib may represent a new therapeutic strategy in completely resected disease.

MDSpire News